Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer
Status:
Completed
Trial end date:
2020-09-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether nintedanib (vargatef®) combined with
docetaxel are effective in second line of treatment in patients with no squamous non small
cell lung cancer refractory to first line chemotherapy.